Pasritamig

Phase 3Biologic

Pasritamig is one of 28 biologic programs targeting Metastatic Castration-resistant Prostate Neoplasms. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Castration-Resistant Prostate NeoplasmsRecruiting

Prostatic Neoplasms, Castration-ResistantRecruiting

Prostatic NeoplasmsRecruiting

Metastatic Castration-Resistant Prostate NeoplasmsPhase 3

Recruiting

Prostatic Neoplasms, Castration-ResistantPhase 3

Recruiting

Prostatic NeoplasmsPhase 3

Recruiting

Competition

Competitive Landscape

21 competitors in Prostatic Neoplasms

#DrugCompanyPhaseTrials

Erleada

Johnson & Johnson

Approved

9 2

Zytiga

Johnson & Johnson

Phase 3

6 3

Xtandi

Astellas

Phase 3

3 4

Verzenio

Eli Lilly

Phase 3

2 5

Rayos

RRoxane Laboratories

Phase 3

4 6

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

3 7

Gnrh

MMassachusetts General Hospital

Phase 3

1 8

Prednisone or Prednisolone

Johnson & Johnson

Phase 3

1 9

Lhrha

Johnson & Johnson

Phase 3

1 10

Trelstar

OOncoVerity, Inc.

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Prostatic Neoplasms

NCT07319871

Q2 2028

Phase 1Recruiting

Metastatic Castration-Resistant Prostate Neoplasms

NCT05818683

Q3 2028

Phase 3Recruiting

Prostatic Neoplasms

NCT07164443

Q3 2029

Phase 3Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT07225946

Clinical

Trials by Indication[1]

Prostatic Neoplasms2 trials

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT07164443·1,203 enrolled

A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT07319871·40 enrolled

Metastatic Castration-resistant Prostate Neoplasms1 trial

A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05818683·300 enrolled

Prostatic Neoplasms, Castration-Resistant1 trial

A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT07225946·800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Pasritamig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pasritamig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pasritamig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Pasritamig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q3 2028

Q3 2029

Trials by Indication[1]

Prostatic Neoplasms2 trials

Metastatic Castration-resistant Prostate Neoplasms1 trial

Prostatic Neoplasms, Castration-Resistant1 trial

References

Drug Info

Quick Facts

Related News